skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Opebacan (Code C114296)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Opebacan

Definition: An injectable formulation composed of opebacan, a 21 kDa recombinant fragment of human bactericidal/permeability-increasing protein (BPI), with potential anti-infective activity. Upon intravenous administration, opebacan is able to mimic BPI and binds to and neutralizes lipopolysaccharides (LPS or endotoxins), which are components of the cell wall of gram-negative bacteria that induce a potent innate immune response. This may prevent an endotoxin-mediated inflammatory response and may prevent graft-versus-host-disease (GvHD) after myeloablative allogeneic hematopoietic stem cell transplantation (aHSCT). BPI, a host-defense protein against microbial infection, is naturally produced by neutrophils. Chemo- and radio-therapy induce neutropenia and depletion of endogenous BPI. These therapies also cause intestinal damage and release of bacterial endotoxins into the bloodstream, which initiate a systemic inflammatory response, activate donor T-lymphocytes and possibly cause GvHD following aHSCT.

Display Name: Opebacan

Label: Opebacan

NCI Thesaurus Code: C114296 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL471807  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
rBPI 21
Recombinant BPI 21 Fragment

External Source Codes: 
PDQ Closed Trial Search ID 758239
PDQ Open Trial Search ID 758239 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C114296
Contributing_Source CTRP
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom